Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Discussing UCB's (Neurona Therapeutics) NRTX-1001 (Allogeneic Cell Therapy) for Drug-Resistant Epilepsy and the Phase 1/2 Data Presented at AAN 2026

Ticker(s): NEURONA THERAPEUTICS, UCBJF, NVS, ABT, JNJ, PFE, ESALF, JAZZ, SNY

Who's the expert?

Institution: UC Davis

Professor of neurology and pharmacology at UC Davis
Internationally recognized expert on drug discovery and development for epilepsy
Research encompasses laboratory studies as well as clinical trials in posttraumautic epilepsy

Interview Goal

To gain a deeper understanding of NRTX-1001 (Allogeneic GABAergic Interneuron Cell Therapy) as a potential treatment for Drug-Resistant Epilepsy

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here To Join
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

12Hours Left to Join Project

Call Date: May 14, 2026
Call Time: 04:30 PM EDT

Wall Street Time

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here To Join
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.